TY - JOUR
AU - Powles, Trevor J
AB - Abstract Placebo controlled trials in over 25,000 women showed that tamoxifen reduced breast cancer risk by about 40% and osteoporotic fracture risk by about 32%. Similarly placebo controlled trials in nearly 18,000 women showed that raloxifene reduced breast cancer risk by 44–72% and osteoporotic fractures risk by 30–50%. A direct comparison of tamoxifen with raloxifene showed similar risk reduction for breast cancer and osteoporotic fractures with less toxicity for raloxifene.
TI - Prevention of breast cancer using selective oestrogen receptor modulators (SERMs)
JF - Breast Cancer Research
DO - 10.1186/bcr1601
DA - 2006-10-01
UR - https://www.deepdyve.com/lp/springer-journals/prevention-of-breast-cancer-using-selective-oestrogen-receptor-6vsAL04HL0
SP - 1
EP - 3
VL - 8
IS - 5
DP - DeepDyve
ER -